The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Open accessAbstract
Nanotechnology has recently gained increased attention for its capability to effectively diagnose and treat various tumors. Nanocarriers have been used to circumvent the problems associated with conventional antitumor drug delivery systems, including their nonspecificity, severe side effects, burst release and damaging the normal cells. Nanocarriers improve the bioavailability and therapeutic efficiency of antitumor drugs, while providing preferential accumulation at the target site. A number of nanocarriers have been developed; however, only a few of them are clinically approved for the delivery of antitumor drugs for their intended actions at the targeted sites. The present review is divided into three main parts: first part presents introduction of various nanocarriers and their relevance in the delivery of anticancer drugs, second part encompasses targeting mechanisms and surface functionalization on nanocarriers and third part covers the description of selected tumors, including breast, lungs, colorectal and pancreatic tumors, and applications of relative nanocarriers in these tumors. This review increases the understanding of tumor treatment with the promising use of nanotechnology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Helical microtubules of graphitic carbon
Iijima, S. (1991) · Nature · doi:10.1038/354056a0 · Cited by 43,098
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Cited by
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Breast cancer: Biology, biomarkers, and treatments
Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi-Kalbolandi, S., Safari, E., & Farahmand, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106535 · Cited by 973
Lombardo, D., Kiselev, M. A., & Caccamo, M. T. (2019) · Journal of Nanomaterials · doi:10.1155/2019/3702518 · Cited by 864
Porous scaffolds for bone regeneration
Abbasi, N., Hamlet, S., Love, R. M., & Nguyen, N.-T. (2020) · Journal of Science: Advanced Materials and Devices · doi:10.1016/j.jsamd.2020.01.007 · Cited by 858
Recent advances in polymeric drug delivery systems
Sung, Y. K., & Kim, S. W. (2020) · Biomaterials Research · doi:10.1186/s40824-020-00190-7 · Cited by 732
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Drug release study of the chitosan-based nanoparticles
Herdiana, Y., Wathoni, N., Shamsuddin, S., & Muchtaridi, M. (2022) · Heliyon · doi:10.1016/j.heliyon.2021.e08674 · Cited by 576
“Furthermore, active targeting and the effects of passive targeting enable polymeric nanoparticles (PNPs) to specifically target cancer cells by detecting the expression of surface receptors on tumours [4, 5, 6, 7].”
BackgroundMagnetic Nanoparticles in Cancer Therapy and Diagnosis
Farzin, A., Etesami, S. A., Quint, J., Memic, A., & Tamayol, A. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901058 · Cited by 562
Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review
Viegas, C., Patrício, A. B., Prata, J. M., Nadhman, A., Chintamaneni, P. K., & Fonte, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061593 · Cited by 524
Nanomedicine review: clinical developments in liposomal applications
Beltrán-Gracia, E., López-Camacho, A., Higuera-Ciapara, I., Velázquez-Fernández, J. B., & Vallejo-Cardona, A. A. (2019) · Cancer Nanotechnology · doi:10.1186/s12645-019-0055-y · Cited by 513
Recent advances in extracellular vesicles for therapeutic cargo delivery
Kim, H. I., Park, J., Zhu, Y., Wang, X., Han, Y., & Zhang, D. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01201-6 · Cited by 505
Barhoum, A., García-Betancourt, M. L., Jeevanandam, J., Hussien, E. A., Mekkawy, S. A., Mostafa, M., Omran, M. M., S. Abdalla, M., & Bechelany, M. (2022) · Nanomaterials · doi:10.3390/nano12020177 · Cited by 447
Emerging trends in the novel drug delivery approaches for the treatment of lung cancer
Sharma, P., Mehta, M., Dhanjal, D. S., Kaur, S., Gupta, G., Singh, H., Thangavelu, L., Rajeshkumar, S., Tambuwala, M., Bakshi, H. A., et al. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.06.033 · Cited by 430
Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy
Raj, S., Khurana, S., Choudhari, R., Kesari, K. K., Kamal, M. A., Garg, N., Ruokolainen, J., Das, B. C., & Kumar, D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.002 · Cited by 425
Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications
Mondal, J., Pillarisetti, S., Junnuthula, V., Saha, M., Hwang, S. R., Park, I.-K., & Lee, Y.-K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.027 · Cited by 416
Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
Edis, Z., Wang, J., Waqas, M. K., Ijaz, M., & Ijaz, M. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s289443 · Cited by 390
Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies
Marques, A. C., Costa, P. J., Velho, S., & Amaral, M. H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.035 · Cited by 349
Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs
Bayón-Cordero, L., Alkorta, I., & Arana, L. (2019) · Nanomaterials · doi:10.3390/nano9030474 · Cited by 344
Applications of nanotechnology in drug delivery to the central nervous system
Saeedi, M., Eslamifar, M., Khezri, K., & Dizaj, S. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.133 · Cited by 342
Recent updates on drug resistance in Mycobacterium tuberculosis
Singh, R., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T. (2020) · Journal of Applied Microbiology · doi:10.1111/jam.14478 · Cited by 337
Kinetic Modeling to Explain the Release of Medicine from Drug Delivery Systems
Askarizadeh, M., Esfandiari, N., Honarvar, B., Sajadian, S. A., & Azdarpour, A. (2023) · ChemBioEng Reviews · doi:10.1002/cben.202300027 · Cited by 318
Sultana, A., Zare, M., Thomas, V., Kumar, T. S. S., & Ramakrishna, S. (2022) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2022.100134 · Cited by 315
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3687700 · Cited by 298
Sharifi-Rad, J., Quispe, C., Butnariu, M., Rotariu, L. S., Sytar, O., Sestito, S., Rapposelli, S., Akram, M., Iqbal, M., Krishna, A., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02025-4 · Cited by 290
Agarwal, H., & Shanmugam, V. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103423 · Cited by 260
Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment
Herdiana, Y., Wathoni, N., Shamsuddin, S., Joni, I. M., & Muchtaridi, M. (2021) · Polymers · doi:10.3390/polym13111717 · Cited by 196
Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles
Souri, M., Soltani, M., Moradi Kashkooli, F., & Kiani Shahvandi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.024 · Cited by 178
Towards principled design of cancer nanomedicine to accelerate clinical translation
Souri, M., Soltani, M., Moradi Kashkooli, F., Kiani Shahvandi, M., Chiani, M., Shariati, F. S., Mehrabi, M. R., & Munn, L. L. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100208 · Cited by 159
Nexus between in silico and in vivo models to enhance clinical translation of nanomedicine
Moradi Kashkooli, F., Soltani, M., Souri, M., Meaney, C., & Kohandel, M. (2021) · Nano Today · doi:10.1016/j.nantod.2020.101057 · Cited by 120
Wu, P., Zhou, Q., Zhu, H., Zhuang, Y., & Bao, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-06803-7 · Cited by 97
RetractedKim, M., Shin, M., Zhao, Y., Ghosh, M., & Son, Y. (2024) · Small Science · doi:10.1002/smsc.202400280 · Cited by 97
Cellular landscaping of cisplatin resistance in cervical cancer
Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., Malik, S., Jha, N. K., Vellingiri, B., Kesari, K. K., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113345 · Cited by 93
Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer
Sharma, M., Bakshi, A. K., Mittapelly, N., Gautam, S., Marwaha, D., Rai, N., Singh, N., Tiwari, P., Agarwal, N., Kumar, A., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.007 · Cited by 84
Ghasemian, M., Kazeminava, F., Naseri, A., Mohebzadeh, S., Abbaszadeh, M., Kafil, H. S., & Ahmadian, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115328 · Cited by 55
Photodynamic therapy of lung cancer, where are we?
Crous, A., & Abrahamse, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.932098 · Cited by 38
Recent Advances in the Development of Magnetic Nanoparticles for Biomedical Applications
Monteserín, M., Larumbe, S., Martínez, A. V., Burgui, S., & Francisco Martín, L. (2021) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2021.19062 · Cited by 27
Askar, M. A., Thabet, N. M., El-sayyad, G. S., El-Batal, A. I., kodous, M. A. E., Kawamura, G., Matsuda, A., Shawi, O. E. E., Helal, H., & Abdel-Rafei, M. K. (2021) · doi:10.21203/rs.3.rs-910507/v1 · Cited by 27
Metadata
- Authors
- Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2017-10
- Volume
- Volume 12
- Pages
- 7291-7309
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2762341360
- Cited by
- 1,577
- References
- 165
- FWCI
- 27.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.